Status:
COMPLETED
Efficacy of Cilostazol in Prevention of Peripheral Neuropathy
Lead Sponsor:
Mansoura University
Conditions:
Peripheral Neuropathy
Breast Cancer
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
PHASE2
Brief Summary
There are several mechanisms concerning pathophysiology of paclitaxel induced peripheral neuropathy. One of the main mechanisms is induction of Schwann cell dedifferentiation by paclitaxel. At the pre...
Eligibility Criteria
Inclusion
- Breast cancer patients who will receive paclitaxel post-anthracycline therapy.
- Eastern Cooperative Oncology Group (ECOG) performance status from 0 to 2.
- Adequate bone marrow function (white blood count ≥4,000/mm3, platelet count≥100,000/mm3), liver function (serum total bilirubin \<1.5 mg/dl), renal function (creatinine \< 1.5 mg/dl).
Exclusion
- Patients with signs and symptoms of clinical neuropathy at baseline.
- Patients with diabetes mellitus or alcoholic disease.
- Patients receiving vitamin/ supplementation drugs that interfere with the study intervention.
Key Trial Info
Start Date :
March 28 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2022
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT05298696
Start Date
March 28 2022
End Date
December 30 2022
Last Update
March 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mansoura University
Al Mansurah, Egypt, 35516